SMS PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 207.4 INR | -0.43% |
|
+0.58% | +74.77% |
| Sales 2022 | 5.2B 62.35M 4.99B | Sales 2023 | 5.22B 62.61M 5.01B | Capitalization | 4.93B 59.14M 4.74B |
|---|---|---|---|---|---|
| Net income 2022 | 622M 7.46M 597M | Net income 2023 | -70M -840K -67.22M | EV / Sales 2022 | 1.94 x |
| Net Debt 2022 | 2.17B 25.99M 2.08B | Net Debt 2023 | 2.47B 29.59M 2.37B | EV / Sales 2023 | 1.42 x |
| P/E ratio 2022 |
12.7
x | P/E ratio 2023 |
-69.9
x | Employees | 1,095 |
| Yield 2022 |
0.32% | Yield 2023 |
0.52% | Free-Float | 27.62% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.43% | ||
| 1 week | +0.58% | ||
| Current month | +16.38% | ||
| 1 month | +15.73% | ||
| 3 months | +65.96% | ||
| 6 months | +75.06% | ||
| Current year | +74.77% |
1 week
205.65
219.40
1 month
177.90219.40
Current year
120.25219.40
1 year
79.40219.40
3 years
54.55219.40
5 years
24.00219.40
10 years
24.00219.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 29/08/90 | |
| Director of Finance/CFO | - | 12/09/17 | |
Tirumalesh Tumma
CMP | Compliance Officer | - | 15/02/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 29/08/90 | |
| Director/Board Member | 60 | 11/08/19 | |
| Director/Board Member | 67 | 11/08/14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 207.4 | -0.43% | 158,164 |
| 25/04/24 | 208.4 | -0.38% | 204,037 |
| 24/04/24 | 209.2 | -1.04% | 224,816 |
| 23/04/24 | 211.4 | -1.33% | 192,959 |
| 22/04/24 | 214.2 | +3.85% | 645,791 |
Delayed Quote NSE India S.E., April 26, 2024 at 12:43 pm
More quotes
SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing of active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel and lamotrigine. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.
Sector
Pharmaceuticals
Calendar
23/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +74.77% | 211M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- SMSPHARMA Stock
